The full version of the official instructions and medication guide for Shafinamide Tablets (Siddaco)

Safinamide tablets (Safinamide) is a new type of reversible and selective monoamine oxidase B (MAO-B) inhibitor. It also has the effect of regulating glutamate release and is mainly used for the adjuvant treatment of Parkinson's disease (PD). Its mechanism of action not only increases dopamine levels in the brain by inhibiting dopamine degradation, but also regulates abnormal glutamate release, thereby improving motor symptoms and may have certain benefits on non-motor symptoms. Shafinide is suitable for patients with mid-to-late Parkinson's disease who suffer from insufficient treatment with dopamine preparations ("on-off" phenomenon) or motor fluctuations, and provides a safe and effective auxiliary medication option for clinical use.

According to the official instructions, the recommended starting dose of safinamide tablets is50 mg once a day, which can be taken orally with a meal. Generally, after 2 weeks of treatment, the dose can be increased to 100 mg once a day based on patient tolerance and efficacy evaluation. Patients should maintain regularity during medication and should not increase or decrease the dosage at will. For elderly patients or those with mild to moderate liver function impairment, they can be used at regular doses; those with severe liver function impairment should use it with caution or avoid use. Patients with impaired renal function usually do not require dose adjustment, but should be flexibly managed based on clinical monitoring results.

Be aware of drug interactions when using safinamide tablets. Because it is a MAO-B inhibitor, combination with non-selective MAO inhibitors or foods and drugs containing high concentrations of tyrosine should be avoided to reduce the risk of hypertensive crisis or serotonin syndrome. At the same time, be cautious when co-administering other central nervous system active drugs, such as tricyclic antidepressants, SSRIs or SNRIs. Patients should inform their doctors of all prescription drugs, over-the-counter drugs, and supplements they are taking while taking the medicine so that the doctor can evaluate potential interactions.

In terms of adverse reactions, the official instructions indicate that the most common adverse events include mild to moderate insomnia, dizziness, nausea, increased blood pressure, and exercise-related symptoms (such as increased muscle tone, worsening tremor). Most adverse reactions can gradually reduce during continued treatment, and a small number of patients may need to adjust the dose or discontinue the drug. Blood pressure and clinical symptoms should be monitored regularly during use, and risk management for patients with a history of cardiovascular disease should be paid attention to.

In terms of patient medication management, safinamide tablets should be stored in a cool, dry place and kept out of reach of children. Before treatment, doctors usually conduct a comprehensive assessment of the patient's motor symptoms, past medication history, and complications, and follow up regularly during the treatment process. Patients should record daily exercise status and fluctuations so that doctors can adjust treatment plans based on efficacy and adverse reactions. Shafinine can be used as an adjuvant treatment with levodopa or dopamine receptor agonists to improve the performanceThe "on-off" phenomenon and extended exercise improvement time have been shown to be effective.

Overall, safinamide tablets provide an effective adjuvant treatment option for Parkinson's patients with its dual mechanism of action and good tolerability. Standardizing medication use, strictly following instructions, and paying attention to drug interactions and adverse reaction monitoring are the keys to ensuring the safety and long-term efficacy of treatment. By regularly evaluating the efficacy and patients' quality of life, doctors can optimize the use of safinamine based on individualized plans to provide patients with Parkinson's disease with sustained and stable movement control and improvement in quality of life.

Reference materials:https://www.drugs.com/